We have previously reported purification of three forms of histamine-releasing factors (HRFs) from mixtures of streptokinase-streptodornase stimulated human mononuclear cells and platelets with apparent molecular masses of 10-12, 15-17, and 4041 kD (1989. J. Clin. Invest. 83:1204-1210. We have also prepared mouse MAbs against the 10-12-kD HRF (1989. J. Allergy Clin. Immunol. 83:281). Affinity-purified 10-12-kD HRF appears as a broad band upon polyacrylamide gel electrophoresis in the presence of SDS. We determined the NH2-terminal amino acid sequence of the top and bottom halves of this broad band. Sequence analysis revealed striking homology between this HRF and connective tissue activating peptide-Ill (CTAP-III), a platelet-derived 8-10-kD protein known to cause mitogenesis and extracellular matrix formation in fibroblast cultures. 19 of 21 NH2-terminal residues in the top half of the HRF band were identical to the NH2-terminal sequence of CTAP-III. 20 of 21 NH2-terminal residues in the bottom half were identical to the NH2-terminal sequence of neutrophil-activating peptide-2, which is derived from CTAP-III by proteolytic cleavage between residues 15 and 16. Purified CTAP-III also released histamine from basophils. Rabbit antiserum raised against either native or recombinant CTAP-IIl recognized affinity-purified HRF in immunodot blot assays, and MAb against HRF recognized C(AP-III in both dot blot and microtiter plate based immunoassays. These data demonstrate the first structural, functional, and immunologic relationship between one form of human HRF and a previously described cell product. (J. Clin. Invest. 1990Invest. . 85:1516Invest. -1521 basophil secretion * histamine release * histamine-releasing factor purification
Introduction
Histamine-releasing factors (HRFs)' are defined as secreted cellular products that interact with basophils and/or mast cells 1. Abbreviations used in this paper: CTAP-III, connective tissue activating factor; HBS, Hepes-buffered saline; HRF, histamine-releasing to release histamine. Originally described as products of human mononuclear cells (MNC) (1, 2) , factors having this property have been found as products ofalveolar macrophages (3), platelets (4), neutrophils (5) , and nasal washings (6) . Most attention has been directed to the products ofhuman MNC (T lymphocytes, B lymphocytes, monocytes), and there is evidence that each of these may be capable of producing HRF (7) (8) (9) , although the products of B lymphocytes may predominate when mixtures are assessed (8) . Although human IL-3 (10), granulocyte-macrophage colony-stimulating factor (10) , and, to a lesser degree, IL-I ( 11) can cause basophil histamine release, the major MNC-derived HRF(s) appear distinct from these and other known cytokines (12, 13) .
We have developed methods for purification of human HRF that is derived from a mixture of streptokinase/streptodornase (SK/SD)-stimulated MNC and platelets. We have isolated molecules of molecular masses 10-12, 15-17, and 40-41 kD, each ofwhich possess histamine-releasing activity (13, 14) . We have also prepared a MAb to the l0-12-kD molecular weight form, which can be used to purify it by affinity chromatography (15) . We now report partial amino acid sequence data of the NH2-terminal region of the 10-12-kD HRF which was found to be strikingly homologous with human connective tissue activating peptide-Il (CTAP-III) (16). A close relationship between this HRF and CTAP-III was confirmed both functionally and immunologically.
Methods
Cell source. Donor lymphopheresis packs were obtained from two sources: normal volunteers after informed consent, or patients undergoing cytopheresis according to an experimental protocol for the treatment of multiple sclerosis. The molecular characterization ofthe HRF described herein did not differ according to source, and the yields of activity appear comparable (14) .
Preparations of cell supernatants. MNC supernatants were prepared as previously described (13, 14) . Briefly, lymphopheresis packs of -200 ml were diluted to 360 ml in Dulbecco's PBS (Gibco Laboratories, Grand Island, NY). 9 .0, and the column was then equilibrated with PBS containing 0.1 mM PMSF, 0.1 mM EDTA, and 0.02% azide (equilibration buffer). All other buffers in this procedure also contained these additives. The same procedure was followed to prepare a precolumn in which the antibody was omitted. Both columns, arranged in tandem, were washed with 100 ml ofequilibration buffer before sample application. 1.5 ml of crude MNC supernatant was applied to the precolumn and its effluent was allowed to pass directly through the MAb 18-1 column. Both columns were washed with the equilibration buffer in tandem until the protein concentration returned to baseline. The columns were then separated, washed with equilibration buffer containing 1.0 M NaCl, and eluted with 3 M KSCN. l-ml fractions were collected. Peak fractions were pooled, dialyzed against 0.05 M ammonium acetate, Iyophilized, and resuspended in 400 Ad of PBS (pH 7.4) containing 0.1 mM PMSF.
Purification of CTAP-III. CTAP-III was isolated from human platelets by acid-ethanol extraction, precipitation with cold acetone, and chromatography over Sephacryl S-200. Final purification was accomplished by immunoaffinity chromatography using monospecific anti-CTAP-III antisera (16).
IL-8/monocyte-derived neutrophil chemotactic peptide (IL-8/ MDNCF). MDNCF was obtained from Dr. E. J. Leonard of the National Cancer Institute, Frederick, MD. Basophil histamine release. The procedures for basophil isolation and histamine release have been described in detail (13) . Briefly, the cells were prepared by dextran sedimentation (0.6% dextran, 0.6% glucose, 0.02% EDTA), the basophil-containing layer was washed twice with Hepes-buffered saline (HBS)-BSA, and the cells were resuspended in HBS-BSA containing 2 mM CaC12, 2 mM MgCl2, and 50% D20. 20-50 ul of each sample or PBS control were incubated with 3 X 106 cells in a total volume of 300 Ad of HBS-HSA containing 2 mM CaC12, 2 mM MgCI2, and 50% D20 for 40 min at 370C and centrifuged at 1,000 g for 5 min. The total basophil histamine content was determined by boiling one of the aliquots. The presence of D20 had no effect on the baseline histamine release and augmented the stimulated histamine release 2-2.5-fold. Therefore it was routinely used to facilitate that assay and conserve reagents.
Histamine assay. The radio enzyme assay for histamine was performed as described by Beaven et al. (18) .
ELISA. ELISA were performed by standard procedures with 96-well microtiter plates (strip 8; Costar, Cambridge, MA). Wells were coated with either 100 ng of affinity-purified HRF or CTAP-III in 100
Ml of PBS (pH 7.4) for 24-48 h at room temperature. Unbound sites were blocked by incubation for 60 min at 370C with 3% BSA in PBS. Wells were then incubated with I Mg/ml murine MAb to HRF in PBS + 0.05% Tween-20 for 2 h, followed by incubation with the secondary antibody (goat anti-mouse IgG and M antibody conjugated to alkaline phosphatase [Jackson Immunoresearch Laboratories Inc., West Grove, PA]) at 1:1,000 dilution for 2 h. After washing, 100 gl of p-nitrophenyl phosphate (1 mg/ml) in I010% diethanolamine-HCI buffer (pH 9.6) was added to the wells and the absorbance read at 405 nm on an ELISA reader (Dynatech Laboratories, Inc., Alexandria, VA).
Gel electrophoresis. SDS-PAGE was performed under nonreducing conditions according to Laemmli (19) .
Preparation ofantisera to CTAP-III. Rabbit antisera to native and recombinant CTAP-III were raised as described previously (20 (Fig. 1 A) and affinity-purified HRF (Fig. 1 z z B) using a 12% (T) gel. This shows a sharp band close to the < < dye front. The same preparation, shown in Fig. 1 that immunologic crossreactivity should be demonstrable. We therefore performed a dot blot of HRF, recombinant CTAP-III, and native CTAP-III with monospecific antibodies to each antigen. All antigens reacted with MAb 18-1 and polyclonal < < < antisera to both native and recombinant CTAP-III recognized HRF as well as CTAP-III (Fig. 2) . We also examined this crossreactivity by ELISA using the MAb 18-1, and assessed its reactivity to HRF, CTAP-III, and a related cytokine, IL-8/ < < MDNCF. Each protein was tested at equal concentrations. As shown in Fig. 3 cause histamine release from basophils (Fig. 4) 1:50 dilution of preimmune rabbit serum (A), rabbit anti-recombinant CTAP-III serum (B), anti-native CTAP-III serum (C), and 0.8 ,tg/ml anti-HRF MAb (D). Dots were developed with horseradish peroxidase-labeled secondary antibodies.
CTAP-III has a molecular weight of 8,000-10,000 by SDS gel electrophoresis and 9,278 D by direct protein sequencing (16). Polyclonal antisera have been developed both to the purified protein and to a recombinant form expressed by Escherichia coli transfected with a synthetic gene for CTAP-III (23) . Both antisera were used in this study and gave the same results. Further, several proteins have now been isolated that are structurally related to CTAP-III; these include fl-thromboglobulin and neutrophil-activating peptide-2 (NAP-2), which are derived from platelet basic protein (24, 25) ; a monocyte-derived factor chemotactic for neutrophils (26) ; a derivative of Rous Sarcoma virus transformed chick embryo fibroblasts (27) ; a growth-regulated gene in transformed Chinese hamster fibroblasts and human cells (28); a melanoma growth-stimulating factor (29); and gene products derived from T and B lymphocytes whose function is as yet unknown (30) . These appear to comprise a family of proteins with significant homology to CTAP-III. However, it is unclear which, if any, are sufficiently related to share epitopes and crossreact immunologically.
We isolated the 12-kD form of HRF using MAb 18-1 and CTAP-III exhibited histamine-releasing activity similar to HRF, although HRF appeared to be relatively more active (Fig. 4) . By contrast, our MAb did not recognize IL-8/ MDNCF/NAP-1, which (a) has a molecular mass of 8 kD, which is in the same range as CTAP-III (25) (35) may be specific for individual components. Our purified factor released histamine in the microgram range, and this is consistent with the microgram quantities of CTAP-III that are required to stimulate DNA synthesis in fibroblast cultures. Since cytokines in general are active in nanogram or picogram quantities, more active histamine-releasing moieties (on a molar basis) may yet be identified. It is also possible that in crude supernatants different components may be acting synergistically, some actively releasing histamine and some others primarily augmenting cell responsiveness (12) .
This study represents the first demonstration that one form of HRF is related to a previously described cell product. Since CTAP-III belongs to a family of proteins related at primary structure level, it will be of interest to determine whether other forms of HRF are homologous to known molecules. This will require not only further sequence analysis ofthe 12-kD moiety described herein, but a similar assessment ofthe other forms of MNC-derived HRF, direct isolation of HRF from purified platelets, and further characterization of HRF derived from other cell types.
